Claims
- 1. A compound of formula I
- 2. The compound according to claim 1 wherein W is SO2.
- 3. The compound according to claim 1 wherein X is O.
- 4. The compound according to claim 1 wherein Y is CR14.
- 5. The compound according to claim 1 wherein n is 1.
- 6. The compound according to claim 2 wherein R12 is an aryl or heteroaryl group each optionally substituted.
- 7. The compound according to claim 6 wherein X is O and n is 1.
- 8. The compound according to claim 7 wherein Y is CR14 and p is 1.
- 9. The compound according to claim 7 selected from the group consisting of
1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(2-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(3-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(4-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(3,4-dimethoxyphenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 4-({4-[2S)-pyrrolidin-2-ylmethoxy]-1H-indole-1-yl}sulfonyl)aniline; 1-(phenylsulfonyl)-4-[(2R)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 8-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)quinoline; 1-[(2-chlorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 1-[(2-fluorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 4-({4-[(2S)-pyrrolidin-2-ylmethoxy}-1H-indazol-1-yl}sulfonyl)aniline; 2-chloro-4-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)aniline; 1-(phenylsulfonyl)-4-(piperidin-2-ylmethoxy)-1H-indole; 4-{[4-(piperidin-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline; 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole; 1-[(3-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole; 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 1-[(2-chlorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 4-(azepan-2-ylmethoxy)-1-(phenylsulfonyl)-1H-indole; 4-{[4-(azepan-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline; 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(3-fluorophenyl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indazole; 4-(azepan-2-ylmethoxy)-1-[(2-chlorophenyl)sulfonyl]-1H-indazole; 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indazole; 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indole; 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indazole; 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indazole; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 10. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
- 11. The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
- 12. The method according to claim 10 wherein said disorder is schizophrenia or depression.
- 13. The method according to claim 11 wherein said disorder is Alzheimer's disease or Parkinson's diease.
- 14. The method according to claim 11 wherein said disorder is attention deficit disorder.
- 15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 16. The composition according to claim 15 having a formula I compound wherein W is SO2.
- 17. The composition according to claim 16 having a formula I wherein X is O.
- 18. The composition according to claim 16 having a formula I compound wherein Y is CR14 and n is 1.
- 19. The composition according to claim 18 having a formula I compound selected from the group consisting of:
1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(2-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(3-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(4-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-[(3,4-dimethoxyphenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole; 4-({4-[2S)-pyrrolidin-2-ylmethoxy]-1H-indole-1-yl}sulfonyl)aniline; 1-(phenylsulfonyl)-4-[(2R)-pyrrolidin-2-ylmethoxy]-1H-indole; 1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 8-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)quinoline; 1-[(2-chlorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 1-[(2-fluorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole; 4-({4-[(2S)-pyrrolidin-2-ylmethoxy}-1H-indazol-1-yl}sulfonyl)aniline; 2-chloro-4-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)aniline; 1-(phenylsulfonyl)-4-(piperidin-2-ylmethoxy)-1H-indole; 4-{[4-(piperidin-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline; 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole; 1-[(3-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole; 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 1-[(2-chlorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole; 4-(azepan-2-ylmethoxy)-1-(phenylsulfonyl)-1H-indole; 4-{[4-(azepan-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline; 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(3-fluorophenyl)sulfonyl]-1H-indole; 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indazole; 4-(azepan-2-ylmethoxy)-1-[(2-chlorophenyl)sulfonyl]-1H-indazole; 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indazole; 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indole; 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indazole; 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indazole; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 20. A process for the preparation of a compound of formula Ie
- 21. A compound of formula XVI
- 22. The compound according to claim 21 wherein X is O; Y is CR14; and n is 1.
- 23. The compound according to claim 22 wherein Z is CR15.
Parent Case Info
[0001] This application claims priority from copending application serial No. 60/285,644, filed on Apr. 20, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60285644 |
Apr 2001 |
US |